Nearly all patients prescribed medical cannabis for anxiety, depression, or PTSD at UK clinics reported meaningful symptom improvement - that is the headline finding from a multi-clinic patient survey published in April 2026, drawing responses from 6,282 patients across Mamedica, Alternaleaf, CB1 Medical, and Curaleaf. Of the 5,128 patients treated specifically for mental health conditions, 97.6% reported symptom improvement, 92.3% noted better sleep quality, and 93.5% said their day-to-day functional ability had improved. The survey, reported by Leafie.co.uk, marks the first time multiple UK medical cannabis clinics have pooled patient-reported outcomes at this scale.
What the Data Actually Says - and What It Doesn't
Patient-reported outcome surveys carry real weight in clinical practice, but they are not randomised controlled trials. The clinics involved were explicit about this: these are cross-sectional, voluntary responses, not blinded efficacy data. Self-selection is a live methodological concern - patients who had a poor experience are less likely to complete a voluntary survey. The clinics are not claiming the results constitute proof of efficacy for these conditions in any regulatory sense, and that restraint matters. Overstating observational findings is exactly the kind of thing that erodes credibility with prescribers, commissioners, and regulators.
What the survey does offer is a substantial signal from real-world clinical practice. 88.3% of respondents said medical cannabis was the most effective treatment they had tried; 90.7% reported it outperformed previous interventions. These are patients who, by the nature of UK prescribing rules, had already exhausted conventional pathways. That context is not incidental - it shapes how the results should be read. This is not a general population sample. It is a cohort of treatment-resistant patients for whom first-line options had failed or proved inappropriate.
Dr. Imogen Kretzschmar, a consultant psychiatrist, observed that the co-occurrence of sleep improvement, reduced anxiety, and better functional capacity is clinically coherent - these outcomes are interdependent, and when they move together, the change is practically significant for patients. She also stressed careful patient selection, risk assessment, and ongoing monitoring, making clear that medical cannabis is not appropriate for all individuals. That kind of measured framing from a clinician embedded in the data is more useful to the sector than promotional enthusiasm.
The Regulatory Architecture Behind UK Medical Cannabis Prescribing
For anyone unfamiliar with how tightly the UK system is structured: only doctors listed on the GMC Specialist Register can prescribe cannabis-based medicinal products, and only when conventional treatments have failed or are clinically inappropriate. Prescribing decisions typically involve multidisciplinary team review. Clinics operate under Care Quality Commission oversight. The products themselves are pharmaceutical-grade, prescription-only medicines - entirely distinct from illicit cannabis in terms of product standards, supply chain traceability, and clinical governance.
This matters for how the survey findings should be interpreted in a B2B context. The patients in this dataset were not self-medicating or accessing unregulated products. They were receiving monitored, documented care within a regulated framework. That distinction affects everything from how outcomes can be attributed to how liability is managed, and it is central to any serious argument the sector wants to make to NHS commissioners or research funders.
The Push for NHS Access and Research Funding
The consortium intends to repeat this survey annually - establishing a recurring benchmark for patient-reported outcomes across participating clinics. That is a sensible institutional move. Longitudinal consistency in data collection is what turns a one-off survey into an evidence base that research councils and health technology assessment bodies can engage with seriously.
The clinics are explicitly calling for government and research council funding for randomised controlled trials in treatment-resistant anxiety, depression, and PTSD. Dr. Simon Erridge of Curaleaf Clinic linked the survey findings to the broader UK Medical Cannabis Registry dataset, arguing that the accumulated evidence supports exploring whether cannabis-based medicinal products could be considered earlier in the treatment pathway - or within NHS commissioning. Mike Barnes, chair of the Medical Cannabis Clinicians Society, put it plainly: the data is "too substantial to set aside."
Here is the practical pressure point. The STAR*D trial data suggests roughly 30% of patients with major depression do not achieve adequate relief after multiple treatment attempts. UK mental health services are operating under sustained demand pressure. If a treatment pathway is consistently producing measurable functional improvement in a cohort that had not responded to standard care, that conversation is eventually going to reach NHS England - with or without RCT data. The question is whether it arrives with rigorous evidence behind it, or without. Jon Robson of Mamedica made the same point, noting consistent improvements "particularly among patients who have already undergone multiple treatment pathways without adequate relief."
Implications for the Licensed Medical Cannabis Sector
For operators in the licensed medical cannabis space, this survey sets a useful precedent on multiple levels. First, collaborative data collection across competing clinics is rare. The decision to pool patient outcomes rather than each clinic publishing independently produces a sample size that commands attention - 6,282 patients is not a pilot study. Second, the framing is careful enough to be defensible. The clinics are making claims about patient-reported experience, not asserting clinical proof of efficacy. That distinction will matter if and when the data is scrutinised by regulators or academic reviewers.
What the sector needs next is exactly what it is asking for: independent, well-funded RCTs. Patient surveys, however large, will always be vulnerable to the methodological critiques that accompany observational data. The annual benchmark model the consortium is building could, over time, generate the kind of longitudinal real-world evidence that meaningfully complements trial data - but it cannot substitute for it. Operators and clinicians who understand that distinction are the ones best positioned to make a credible case to commissioners, funders, and policymakers.
